BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Nasdaq/NYSE listing notice — Brainstorm Cell receives Nasdaq bid price deficiency notice; has until April 29, 2024 to comply

BRAINSTORM CELL THERAPEUTICS INC.

Nasdaq notified BCLI on Nov 1, 2023 of non-compliance with $1.00 minimum bid price rule (Listing Rule 5550(a)(2)).
No immediate delisting; stock continues trading on Nasdaq Capital Market under symbol BCLI.
Company has 180 days, until April 29, 2024, to regain compliance by closing at or above $1.00 for 10 consecutive business days.
If not compliant by April 29, BCLI may qualify for an additional 180-day compliance period if other listing standards are met.
Company intends to monitor bid price and take reasonable measures, but there is no assurance of regaining compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(H), 5810(c)(3)(A)(ii)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(H), 5810(c)(3)(A)(ii)

Exact text from the filing

November 1, 2023, Brainstorm Cell Therapeutics Inc. (the “Company”) received a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Bid Price Deficiency Notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on th

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-114279

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.